Investors & Media

Corporate Profile

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. More than 100 million Americans suffer from chronic or acute pain, while another 100 million suffer from various neurological disorders, including migraines, low back pain and neck pain.1 Pain medications are often used to help treat these conditions.

Many patients experiencing moderate to severe pain receive prescription opioids, though treatment with opioids comes with inherent risks. Neumentum’s analgesic product candidates have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization. Neumentum has global rights to five novel non-opioid pain products, the most advanced of which are two phase 3-ready injectable products under development for acute postsurgical pain.

Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at BIO CEO and Investor Conference in New York

Scott Shively, Chief Executive Officer, will present at the BIO CEO and Investor Conference held February, 10 – 11, 2020 at the Marriot Marquis in New York City

Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2020 Biotech Showcase in San Francisco, CA

Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2020 Biotech Showcase being held January 13-15, 2020 in San Francisco, CA.